prikaz prve stranice dokumenta Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use
  Preuzmi
PDF 1.06 MB
Znanstveni rad - Izvorni znanstveni rad
Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use
Journal of Psychopharmacology, 38 (2024), 4; 395-403. https://doi.org/10.1177/02698811241237868
Papić, Ivan; Bistrović, Petra; Krečak, Ivan; Ortner Hadžiabdić, Maja; Lucijanić, Marko

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Papić, I., Bistrović, P., Krečak, I., Ortner Hadžiabdić, M. i Lucijanić, M. (2024). Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use. Journal of Psychopharmacology, 38. (4), 395-403. doi: 10.1177/02698811241237868

Papić, Ivan, et al. "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use." Journal of Psychopharmacology, vol. 38, br. 4, 2024, str. 395-403. https://doi.org/10.1177/02698811241237868

Papić, Ivan, Petra Bistrović, Ivan Krečak, Maja Ortner Hadžiabdić i Marko Lucijanić. "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use." Journal of Psychopharmacology 38, br. 4 (2024): 395-403. https://doi.org/10.1177/02698811241237868

Papić, I., et al. (2024) 'Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use', Journal of Psychopharmacology, 38(4), str. 395-403. doi: 10.1177/02698811241237868

Papić I, Bistrović P, Krečak I, Ortner Hadžiabdić M, Lucijanić M. Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use. Journal of Psychopharmacology [Internet]. 13.03.2024. [pristupljeno 02.01.2025.];38(4):395-403. doi: 10.1177/02698811241237868

I. Papić, P. Bistrović, I. Krečak, M. Ortner Hadžiabdić i M. Lucijanić, "Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use", Journal of Psychopharmacology, vol. 38, br. 4, str. 395-403, Ožujak 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:413758. [Citirano: 02.01.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:413758
Podaci o radu
Naslov (engleski)Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use
AutorIvan Papić
AutorPetra Bistrović
AutorIvan Krečak
AutorMaja Ortner Hadžiabdić
AutorMarko Lucijanić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background: Due to non-consistent reports in the literature, there are uncertainties about the potential benefits and harms of selective serotonin reuptake inhibitors (SSRIs) in patients with Coronavirus disease 2019 (COVID-19). Aim: To investigate associations of SSRIs with clinical characteristics and unwanted outcomes among real-life severe and critical COVID-19 patients and their relationship with remdesivir (RDV) use. Methods: This retrospective cohort study evaluated a total of 1558 COVID-19 patients of the white race treated in a tertiary center institution, among them 779 patients treated with RDV and 779 1:1 case-matched patients. Results: A total of 78 (5%) patients were exposed to SSRIs during hospitalization, similarly distributed among patients treated with RDV and matched patients (5.1 and 4.9%). No significant associations of SSRI use with age, sex, comorbidity burden, and COVID-19 severity were present in either of the two cohorts (p > 0.05 for all analyses). In multivariate analyses adjusted for clinically meaningful variables, SSRI use was significantly associated with higher mortality among RDV (adjusted odds ratio (aOR) 2.0, p = 0.049) and matched patients (aOR 2.22, p = 0.044) and with higher risk for mechanical-ventilation (aOR 2.57, p = 0.006), venous-thromboembolism (aOR 3.69, p = 0.007), and bacteremia (aOR 2.22, p = 0.049) among RDV treated patients. Conclusions: Adverse outcomes associated with SSRI use in COVID-19 patients might be potentiated by RDV use, and clinically significant interactions between these two drug classes might exist. Although our findings raise important considerations for clinical practice, they are limited by retrospective nature of the study, lack of ethnic diversity, and the potential for unmeasured confounding factors. Future studies exploring underlying biological mechanisms are needed.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Psychopharmacology
Brojčani podacivol. 38, br. 4, str. 395-403
p-ISSN0269-8811
e-ISSN1461-7285
DOIhttps://doi.org/10.1177/02698811241237868
URN:NBNurn:nbn:hr:105:413758
Datum objave publikacije2024-03-13
URL dokumentahttps://journals.sagepub.com/doi/10.1177/02698811241237868
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-11-25 08:47:52